Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma | Synapse

August 21, 2019New England Journal of Medicine684 citationsOpen Access

Ver artículo completo

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

ACAjai ChariUniversity of California, San Francisco DVDan T. VoglUniversity of Pennsylvania MGMaria GavriatopoulouNational and Kapodistrian University of Athens

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies. (Funded by Karyopharm Therapeutics; STORM ClinicalTrials.gov number, NCT02336815.).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Chari et al. (Wed,) studied this question.

synapsesocial.com/papers/69dd5da77dbdc4ad1440c67c https://doi.org/https://doi.org/10.1056/nejmoa1903455

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Functional characterization of somatic mutations in cancer using network-based inference of protein activity2016 · 1,090 citations
2Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM12013 · 196 citations
3Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer2008 · 216 citations
4Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis2012 · 139 citations
5Neural networks for pattern recognition1994 · 18,724 citations